149 related articles for article (PubMed ID: 19232460)
1. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
Yu Z; Wu J; Wu S; Jia P; Tong Y; Wu X; Wang Y
Cancer Lett; 2009 Jun; 279(1):101-7. PubMed ID: 19232460
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
Harada H; Hiraoka M; Kizaka-Kondoh S
Cancer Res; 2002 Apr; 62(7):2013-8. PubMed ID: 11929818
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
4. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia.
Shahrzad S; Lacombe K; Adamcic U; Minhas K; Coomber BL
Cancer Lett; 2010 Nov; 297(1):75-83. PubMed ID: 20537792
[TBL] [Abstract][Full Text] [Related]
5. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
6. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
Kudo T; Ueda M; Kuge Y; Mukai T; Tanaka S; Masutani M; Kiyono Y; Kizaka-Kondoh S; Hiraoka M; Saji H
J Nucl Med; 2009 Jun; 50(6):942-9. PubMed ID: 19443598
[TBL] [Abstract][Full Text] [Related]
7. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia and HIF1alpha repress the differentiative effects of BMPs in high-grade glioma.
Pistollato F; Chen HL; Rood BR; Zhang HZ; D'Avella D; Denaro L; Gardiman M; te Kronnie G; Schwartz PH; Favaro E; Indraccolo S; Basso G; Panchision DM
Stem Cells; 2009 Jan; 27(1):7-17. PubMed ID: 18832593
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells.
Michiue H; Tomizawa K; Matsushita M; Tamiya T; Lu YF; Ichikawa T; Date I; Matsui H
FEBS Lett; 2005 Jul; 579(18):3965-9. PubMed ID: 15996664
[TBL] [Abstract][Full Text] [Related]
10. TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkin-mediated mitophagy.
Zheng R; Yao Q; Xie G; Du S; Ren C; Wang Y; Yuan Y
Oncotarget; 2015 Jul; 6(19):17417-29. PubMed ID: 26025927
[TBL] [Abstract][Full Text] [Related]
11. Activating transcription factor 2 increases transactivation and protein stability of hypoxia-inducible factor 1alpha in hepatocytes.
Choi JH; Cho HK; Choi YH; Cheong J
Biochem J; 2009 Nov; 424(2):285-96. PubMed ID: 19712049
[TBL] [Abstract][Full Text] [Related]
12. Rational design of shepherdin, a novel anticancer agent.
Plescia J; Salz W; Xia F; Pennati M; Zaffaroni N; Daidone MG; Meli M; Dohi T; Fortugno P; Nefedova Y; Gabrilovich DI; Colombo G; Altieri DC
Cancer Cell; 2005 May; 7(5):457-68. PubMed ID: 15894266
[TBL] [Abstract][Full Text] [Related]
13. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
Zavaglia D; Lin EH; Guidetti M; Pluquet O; Hainaut P; Favrot MC; Coll JL
J Gene Med; 2005 Jul; 7(7):936-44. PubMed ID: 15754307
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenesis and anti-tumor activity of recombinant anginex.
Brandwijk RJ; Dings RP; van der Linden E; Mayo KH; Thijssen VL; Griffioen AW
Biochem Biophys Res Commun; 2006 Oct; 349(3):1073-8. PubMed ID: 16970922
[TBL] [Abstract][Full Text] [Related]
15. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.
Sacco E; Metalli D; Spinelli M; Manzoni R; Samalikova M; Grandori R; Morrione A; Traversa S; Alberghina L; Vanoni M
Biotechnol Adv; 2012; 30(1):233-43. PubMed ID: 21620943
[TBL] [Abstract][Full Text] [Related]
16. Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice.
Hsieh CH; Kuo JW; Lee YJ; Chang CW; Gelovani JG; Liu RS
J Nucl Med; 2009 Dec; 50(12):2049-57. PubMed ID: 19910419
[TBL] [Abstract][Full Text] [Related]
17. Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor.
Zou Y; Chen Y; Jiang Y; Gao J; Gu J
Cancer Res; 2007 Aug; 67(15):7295-300. PubMed ID: 17671198
[TBL] [Abstract][Full Text] [Related]
18. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.
Wouters A; Pauwels B; Lambrechts HA; Pattyn GG; Ides J; Baay M; Meijnders P; Dewilde S; Vermorken JB; Lardon F
Cancer Lett; 2009 Dec; 286(2):180-8. PubMed ID: 19540039
[TBL] [Abstract][Full Text] [Related]
20. Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice.
Michod D; Annibaldi A; Schaefer S; Dapples C; Rochat B; Widmann C
J Natl Cancer Inst; 2009 Jun; 101(11):828-32. PubMed ID: 19470951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
